<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Fri, 16 Oct 2026 09:11:55 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Schrodinger (SDGR) PT Raised to $32 at KeyBanc</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Schrodinger+%28SDGR%29+PT+Raised+to+%2432+at+KeyBanc/27196263.html</link>
   <description>KeyBanc analyst Scott Schoenhaus raised the price target on Schrodinger (NASDAQ: SDGR) to $32.00  (from $20.00) while maintaining a Overweight rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Schrodinger+%28SDGR%29+PT+Raised+to+%2432+at+KeyBanc/27196263.html</guid>
   <pubDate>Fri, 16 Oct 2026 09:11:55 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry</title>
   <link>http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Research+Published+in+Nature+Reveals+New+Insights+into+Lithium-Ion+Battery+Chemistry/27185780.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New study uncovers multi-lithium ion clustering in common battery electrolytes, paving the way for improved battery performance and design&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR) today announced the publication of new research in &lt;i&gt;Nature &lt;/i&gt;that reveals critical insights into the atomic-scale structure of lithium-ion battery (LIB) electrolytes. In a joint study with researchers from Columbia University and the New York Structural Biology Center, the team discovered new insights that challenge long-held assumptions of the fundamental chemistry of lithium-ion batteries, including multi-lithium ion complexes that may play an important role in electrolyte behavior and battery function. These</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Research+Published+in+Nature+Reveals+New+Insights+into+Lithium-Ion+Battery+Chemistry/27185780.html</guid>
   <pubDate>Wed, 14 Oct 2026 11:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrödinger Research Published in Nature Reveals New Insights into Lithium-Ion Battery Chemistry</title>
   <link>http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Research+Published+in+Nature+Reveals+New+Insights+into+Lithium-Ion+Battery+Chemistry/27185780.html</link>
   <description>
&lt;p class=&quot;bwalignc&quot;&gt;
&lt;i&gt;New study uncovers multi-lithium ion clustering in common battery electrolytes, paving the way for improved battery performance and design&lt;/i&gt;

&lt;/p&gt;
&lt;p&gt;    NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR) today announced the publication of new research in &lt;i&gt;Nature &lt;/i&gt;that reveals critical insights into the atomic-scale structure of lithium-ion battery (LIB) electrolytes. In a joint study with researchers from Columbia University and the New York Structural Biology Center, the team discovered new insights that challenge long-held assumptions of the fundamental chemistry of lithium-ion batteries, including multi-lithium ion complexes that may play an important role in electrolyte behavior and battery function. These</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Research+Published+in+Nature+Reveals+New+Insights+into+Lithium-Ion+Battery+Chemistry/27185780.html</guid>
   <pubDate>Wed, 14 Oct 2026 11:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrodinger (SDGR) PT Raised to $31 at TD Cowen</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Schrodinger+%28SDGR%29+PT+Raised+to+%2431+at+TD+Cowen/27178957.html</link>
   <description>TD Cowen analyst Brendan Smith raised the price target on Schrodinger (NASDAQ: SDGR) to $31.00  (from $20.00) while maintaining a  rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Schrodinger+%28SDGR%29+PT+Raised+to+%2431+at+TD+Cowen/27178957.html</guid>
   <pubDate>Tue, 13 Oct 2026 09:39:17 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrodinger (SDGR) PT Raised to $30 at BMO Capital</title>
   <link>http://www.streetinsider.com/Analyst+PT+Change/Schrodinger+%28SDGR%29+PT+Raised+to+%2430+at+BMO+Capital/27174718.html</link>
   <description>BMO Capital analyst Evan David Seigerman raised the price target on Schrodinger (NASDAQ: SDGR) to $30.00  (from $24.00) while maintaining a Outperform rating.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+PT+Change/Schrodinger+%28SDGR%29+PT+Raised+to+%2430+at+BMO+Capital/27174718.html</guid>
   <pubDate>Mon, 12 Oct 2026 09:53:45 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Form  4          Schrodinger, Inc.         For: Sep 17  Filed by: Akinsanya Karen</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Schrodinger%2C+Inc.+++++++++For%3A+Sep+17++Filed+by%3A+Akinsanya+Karen/27086046.html</link>
   <description>si-local-file:///var/storage/secattach/20260921/27086046.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Schrodinger%2C+Inc.+++++++++For%3A+Sep+17++Filed+by%3A+Akinsanya+Karen/27086046.html</guid>
   <pubDate>Mon, 21 Sep 2026 17:15:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Form  144        Schrodinger, Inc.                      Filed by: Akinsanya Karen</title>
   <link>http://www.streetinsider.com/SEC+Filings/Form++144++++++++Schrodinger%2C+Inc.++++++++++++++++++++++Filed+by%3A+Akinsanya+Karen/27076212.html</link>
   <description>si-local-file:///var/storage/secattach/20260917/27076212.html</description>
   <guid isPermaLink="true">http://www.streetinsider.com/SEC+Filings/Form++144++++++++Schrodinger%2C+Inc.++++++++++++++++++++++Filed+by%3A+Akinsanya+Karen/27076212.html</guid>
   <pubDate>Thu, 17 Sep 2026 16:28:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrodinger Inc. (SDGR) 1500 contracts of March 35 calls as share price up 21%</title>
   <link>http://www.streetinsider.com/Options/Schrodinger+Inc.+%28SDGR%29+1500+contracts+of+March+35+calls+as+share+price+up+21%25/27075421.html</link>
   <description>&lt;p&gt;Schrodinger Inc. (NASDAQ: SDGR) 30-day option implied volatility is at 80; compared to its 52-week range of 46 to 109. Call put ratio 9.9 calls to 1 put with a focus on 1500 contracts of March 35 calls as share price up 21%.&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Options/Schrodinger+Inc.+%28SDGR%29+1500+contracts+of+March+35+calls+as+share+price+up+21%25/27075421.html</guid>
   <pubDate>Thu, 17 Sep 2026 15:05:41 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Increasing unusual call option volume: JETS XP SDGR GRPO SECZ MAT SABR GNRC PTON AVL COHX CYPH ACAD</title>
   <link>http://www.streetinsider.com/Options/Increasing+unusual+call+option+volume%3A+JETS+XP+SDGR+GRPO+SECZ+MAT+SABR+GNRC+PTON+AVL+COHX+CYPH+ACAD/27074171.html</link>
   <description>&lt;p&gt;Increasing unusual call option volume: JETS XP SDGR GRPO SECZ MAT SABR GNRC PTON AVL COHX CYPH ACAD&lt;/p&gt;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Options/Increasing+unusual+call+option+volume%3A+JETS+XP+SDGR+GRPO+SECZ+MAT+SABR+GNRC+PTON+AVL+COHX+CYPH+ACAD/27074171.html</guid>
   <pubDate>Thu, 17 Sep 2026 10:20:24 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
   <link>http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27073168.html</link>
   <description>
&lt;p&gt;    NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company’s common stock to three newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27073168.html</guid>
   <pubDate>Thu, 17 Sep 2026 08:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
   <link>http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27073168.html</link>
   <description>
&lt;p&gt;    NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on September 13, 2026, the company granted restricted stock units (RSUs) with respect to 2,243 shares of the company’s common stock to three newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/27073168.html</guid>
   <pubDate>Thu, 17 Sep 2026 08:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
   <link>http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26925105.html</link>
   <description>
&lt;p&gt;    NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26925105.html</guid>
   <pubDate>Fri, 14 Aug 2026 08:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.46871614</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
   <link>http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26925105.html</link>
   <description>
&lt;p&gt;    NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26925105.html</guid>
   <pubDate>Fri, 14 Aug 2026 08:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.46871614</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
   <link>http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26925105.html</link>
   <description>
&lt;p&gt;    NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26925105.html</guid>
   <pubDate>Fri, 14 Aug 2026 08:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.46871614</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)</title>
   <link>http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26925105.html</link>
   <description>
&lt;p&gt;    NEW YORK--(BUSINESS WIRE)--
Schrödinger, Inc. (Nasdaq: SDGR) today reported that on August 12, 2026, the company granted restricted stock units (RSUs) with respect to 3,315 shares of the company’s common stock to two newly hired employees. These grants were made pursuant to the company’s 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company’s board of directors, and were made as a material inducement to such employees’ acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Business+Wire/Schr%C3%B6dinger+Reports+Inducement+Grants+under+Nasdaq+Listing+Rule+5635%28c%29%284%29/26925105.html</guid>
   <pubDate>Fri, 14 Aug 2026 08:30:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">O.46871614</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>UBS Starts Schrodinger (SDGR) at Neutral</title>
   <link>http://www.streetinsider.com/New+Coverage/UBS+Starts+Schrodinger+%28SDGR%29+at+Neutral/26923631.html</link>
   <description>&lt;p&gt;UBS analyst Kevin Caliendo initiates coverage on Schrodinger (NASDAQ: SDGR) with a Neutral rating and a price target of $19.00.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;We assume coverage of SDGR at Neutral with a $19 price target. We believe the market is currently pricing in a 3-yr Software growth CAGR of ~15% (FY26-FY29) with EBITDA turning positive by FY28. We are forecasting ~16% Software growth over that period, but with a lack of clear catalysts over the next 12 months, we would like to see SDGR's transition to a software-centric, drug discovery model gain traction before potentially taking an active view on shares.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/New+Coverage/UBS+Starts+Schrodinger+%28SDGR%29+at+Neutral/26923631.html</guid>
   <pubDate>Fri, 14 Aug 2026 05:51:56 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>UBS Starts Schrodinger (SDGR) at Neutral</title>
   <link>http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Schrodinger+%28SDGR%29+at+Neutral/26923631.html</link>
   <description>&lt;p&gt;UBS analyst Kevin Caliendo initiates coverage on Schrodinger (NASDAQ: SDGR) with a Neutral rating and a price target of $19.00.&lt;/p&gt;&lt;p&gt;The analyst comments &quot;We assume coverage of SDGR at Neutral with a $19 price target. We believe the market is currently pricing in a 3-yr Software growth CAGR of ~15% (FY26-FY29) with EBITDA turning positive by FY28. We are forecasting ~16% Software growth over that period, but with a lack of clear catalysts over the next 12 months, we would like to see SDGR's transition to a software-centric, drug discovery model gain traction before potentially taking an active view on shares.</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Analyst+Comments/UBS+Starts+Schrodinger+%28SDGR%29+at+Neutral/26923631.html</guid>
   <pubDate>Fri, 14 Aug 2026 05:51:56 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	  </item>
  <item>
   <title>AI Found an Influenza Target That Survives Viral Mutation</title>
   <link>http://www.streetinsider.com/Press+Releases/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;left&quot;&gt;AUSTIN, Texas, Aug.  10, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=6PG_U1c75vLehmlhO-Bv1jX1ArWZX_ZqgNeG2LKoFAU8pO9p4nQ_sRN3qXbamRuFqPXw_RUbf7xsqzCwkwzmiOvwu-GypDfKGNAMo-YjdH8=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Equity Insider&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=nvAsHf58Mtce76-DaNUnR_lltY13LV4MpIiQt3STUmCnoxH9EdpqdaOuw0EiuSy1Vdq7DNSm5z-0b2GxGDvmuWkSPh0xtlmgx9dWmfKROpk=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;MindWalk Holdings Corp.&lt;/a&gt; (Nasdaq: HYFT) has built its entire technology stack around that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</guid>
   <pubDate>Mon, 10 Aug 2026 09:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABCL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TEM</category>
   	  </item>
  <item>
   <title>AI Found an Influenza Target That Survives Viral Mutation</title>
   <link>http://www.streetinsider.com/Globe+Newswire/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;left&quot;&gt;AUSTIN, Texas, Aug.  10, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=6PG_U1c75vLehmlhO-Bv1jX1ArWZX_ZqgNeG2LKoFAU8pO9p4nQ_sRN3qXbamRuFqPXw_RUbf7xsqzCwkwzmiOvwu-GypDfKGNAMo-YjdH8=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Equity Insider&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=nvAsHf58Mtce76-DaNUnR_lltY13LV4MpIiQt3STUmCnoxH9EdpqdaOuw0EiuSy1Vdq7DNSm5z-0b2GxGDvmuWkSPh0xtlmgx9dWmfKROpk=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;MindWalk Holdings Corp.&lt;/a&gt; (Nasdaq: HYFT) has built its entire technology stack around that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</guid>
   <pubDate>Mon, 10 Aug 2026 09:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABCL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TEM</category>
   	  </item>
  <item>
   <title>AI Found an Influenza Target That Survives Viral Mutation</title>
   <link>http://www.streetinsider.com/Press+Releases/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;left&quot;&gt;AUSTIN, Texas, Aug.  10, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=6PG_U1c75vLehmlhO-Bv1jX1ArWZX_ZqgNeG2LKoFAU8pO9p4nQ_sRN3qXbamRuFqPXw_RUbf7xsqzCwkwzmiOvwu-GypDfKGNAMo-YjdH8=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Equity Insider&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=nvAsHf58Mtce76-DaNUnR_lltY13LV4MpIiQt3STUmCnoxH9EdpqdaOuw0EiuSy1Vdq7DNSm5z-0b2GxGDvmuWkSPh0xtlmgx9dWmfKROpk=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;MindWalk Holdings Corp.&lt;/a&gt; (Nasdaq: HYFT) has built its entire technology stack around that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</guid>
   <pubDate>Mon, 10 Aug 2026 09:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABCL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TEM</category>
   	  </item>
  <item>
   <title>AI Found an Influenza Target That Survives Viral Mutation</title>
   <link>http://www.streetinsider.com/Globe+Newswire/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;left&quot;&gt;AUSTIN, Texas, Aug.  10, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=6PG_U1c75vLehmlhO-Bv1jX1ArWZX_ZqgNeG2LKoFAU8pO9p4nQ_sRN3qXbamRuFqPXw_RUbf7xsqzCwkwzmiOvwu-GypDfKGNAMo-YjdH8=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Equity Insider&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=nvAsHf58Mtce76-DaNUnR_lltY13LV4MpIiQt3STUmCnoxH9EdpqdaOuw0EiuSy1Vdq7DNSm5z-0b2GxGDvmuWkSPh0xtlmgx9dWmfKROpk=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;MindWalk Holdings Corp.&lt;/a&gt; (Nasdaq: HYFT) has built its entire technology stack around that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</guid>
   <pubDate>Mon, 10 Aug 2026 09:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABCL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TEM</category>
   	  </item>
  <item>
   <title>AI Found an Influenza Target That Survives Viral Mutation</title>
   <link>http://www.streetinsider.com/Press+Releases/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;left&quot;&gt;AUSTIN, Texas, Aug.  10, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=6PG_U1c75vLehmlhO-Bv1jX1ArWZX_ZqgNeG2LKoFAU8pO9p4nQ_sRN3qXbamRuFqPXw_RUbf7xsqzCwkwzmiOvwu-GypDfKGNAMo-YjdH8=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Equity Insider&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=nvAsHf58Mtce76-DaNUnR_lltY13LV4MpIiQt3STUmCnoxH9EdpqdaOuw0EiuSy1Vdq7DNSm5z-0b2GxGDvmuWkSPh0xtlmgx9dWmfKROpk=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;MindWalk Holdings Corp.&lt;/a&gt; (Nasdaq: HYFT) has built its entire technology stack around that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</guid>
   <pubDate>Mon, 10 Aug 2026 09:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABCL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TEM</category>
   	  </item>
  <item>
   <title>AI Found an Influenza Target That Survives Viral Mutation</title>
   <link>http://www.streetinsider.com/Globe+Newswire/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;left&quot;&gt;AUSTIN, Texas, Aug.  10, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=6PG_U1c75vLehmlhO-Bv1jX1ArWZX_ZqgNeG2LKoFAU8pO9p4nQ_sRN3qXbamRuFqPXw_RUbf7xsqzCwkwzmiOvwu-GypDfKGNAMo-YjdH8=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Equity Insider&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=nvAsHf58Mtce76-DaNUnR_lltY13LV4MpIiQt3STUmCnoxH9EdpqdaOuw0EiuSy1Vdq7DNSm5z-0b2GxGDvmuWkSPh0xtlmgx9dWmfKROpk=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;MindWalk Holdings Corp.&lt;/a&gt; (Nasdaq: HYFT) has built its entire technology stack around that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</guid>
   <pubDate>Mon, 10 Aug 2026 09:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABCL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TEM</category>
   	  </item>
  <item>
   <title>AI Found an Influenza Target That Survives Viral Mutation</title>
   <link>http://www.streetinsider.com/Press+Releases/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;left&quot;&gt;AUSTIN, Texas, Aug.  10, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=6PG_U1c75vLehmlhO-Bv1jX1ArWZX_ZqgNeG2LKoFAU8pO9p4nQ_sRN3qXbamRuFqPXw_RUbf7xsqzCwkwzmiOvwu-GypDfKGNAMo-YjdH8=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Equity Insider&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=nvAsHf58Mtce76-DaNUnR_lltY13LV4MpIiQt3STUmCnoxH9EdpqdaOuw0EiuSy1Vdq7DNSm5z-0b2GxGDvmuWkSPh0xtlmgx9dWmfKROpk=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;MindWalk Holdings Corp.&lt;/a&gt; (Nasdaq: HYFT) has built its entire technology stack around that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</guid>
   <pubDate>Mon, 10 Aug 2026 09:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABCL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TEM</category>
   	  </item>
  <item>
   <title>AI Found an Influenza Target That Survives Viral Mutation</title>
   <link>http://www.streetinsider.com/Globe+Newswire/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</link>
   <description>&lt;p&gt;&lt;strong&gt;Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)&lt;/strong&gt;&lt;/p&gt;&lt;p align=&quot;left&quot;&gt;AUSTIN, Texas, Aug.  10, 2026  (GLOBE NEWSWIRE) -- &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=6PG_U1c75vLehmlhO-Bv1jX1ArWZX_ZqgNeG2LKoFAU8pO9p4nQ_sRN3qXbamRuFqPXw_RUbf7xsqzCwkwzmiOvwu-GypDfKGNAMo-YjdH8=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;Equity Insider&lt;/a&gt; &lt;strong&gt;News Commentary&lt;/strong&gt; - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. &lt;a href=&quot;https://www.globenewswire.com/Tracker?data=nvAsHf58Mtce76-DaNUnR_lltY13LV4MpIiQt3STUmCnoxH9EdpqdaOuw0EiuSy1Vdq7DNSm5z-0b2GxGDvmuWkSPh0xtlmgx9dWmfKROpk=&quot; rel=&quot;nofollow&quot; target=&quot;_blank&quot;&gt;MindWalk Holdings Corp.&lt;/a&gt; (Nasdaq: HYFT) has built its entire technology stack around that</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/AI+Found+an+Influenza+Target+That+Survives+Viral+Mutation/26895427.html</guid>
   <pubDate>Mon, 10 Aug 2026 09:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">ABCL</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">AMD</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">HYFT</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">SDGR</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">TEM</category>
   	  </item>
 </channel>
</rss>
